Demethylation of miR-195 suppresses prostate cancer cell proliferation, migration and invasion

Xiaokun Ma1, Liyuan Zou2, Zhanhong Chen1, Xing Li1, Li Wei1 and Xiangyuan Wu1

1 Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 Department of Prevention and Health Care, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Keywords
methylation; miR-195; prostate cancer; tumor suppressor

Correspondence
X. Wu, Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Tianhe, Guangzhou 510630, China
E-mail: drxiangyuanwu@126.com

Xiaokun Ma and Liyuan Zou contributed equally to this article

(Received 5 September 2019, revised 20 December 2019, accepted 20 January 2020)
doi:10.1002/2211-5463.12799

Prostate cancer (PCa) is the most prevalent cancer among men and the second leading cause of tumor-associated deaths worldwide, with increasing incidence rates over the last 10 years [1,2]. Early PCa may be managed by radical prostatectomy, but a majority of patients eventually experience metastatic disease [3]. Prostate tumors contain marked heterogeneous phenotypes with various survival rates from 2–3 years to 10–20 years, reflecting the potential genomic diversity [4]. Nowadays, involvement of numerous genes in the regulation of PCa has attracted great public interest, but the molecular mechanisms underlying this malignancy have not been fully elucidated.

Widespread epigenomic dysregulation events as a hallmark of tumorigenesis frequently occur in PCa according to recent studies [5–7]. As one of the epigenetic alterations, aberrant tumor-specific DNA methylation causes gene expression repression alterations, which are an emerging class of therapeutic targets for prostate carcinogenesis [8–11]. As noncoding small RNA molecules (19–25 nucleotides), microRNAs (miRNAs) play a vital role in cellular functions, including proliferation, apoptosis and invasion in human diseases, through interacting with mRNAs [12,13]. Up-regulated miRNAs function as oncogenes targeting tumor suppressor genes [14,15], whereas down-regulated miRNAs exert as tumor suppressors targeting oncogenes in PCa [16–18]. Notably, it has been suggested that inhibition of tumor suppressor miRNAs by DNA methylation is a widely accepted mechanism in the development of tumors, including PCa [19].

MicroRNA-195 (miR-195) is mapped to chromosome 17p13.1 and is one of the miR-15/107 family members
with a similar sequence (AGCAGC) [20]. Accumulating evidence suggests that abnormal expression of miR-195 may contribute to the pathogenesis of many diseases, including Alzheimer’s disease [21], heart failure [22] and cerebral ischemia [23]. Recently, miR-195 was identified as being down-regulated in several tumor tissues, such as breast cancer [24], cervical cancer [25] and hepatocellular carcinoma (HCC) [26], which acts as tumor suppressor via targeting the mRNAs of multiple proteins. In particular, miR-195 is frequently reported to suppress cell proliferation and metastasis by targeting RPS6KB1 [27], BC0X1 [28], fibroblast growth factor 2 (FGF2) [29] and PRR11 [30], as well as enhance drug resistance in PCs [31,32]. Interestingly, He et al. [33] found that miR-195 was silenced by promoter CpG island hypermethylation in HCC [33].

In this study, we first analyzed the profile of miR-195, as well as the DNA methylation of its promoter in PCa tissues. Then, we explored the impact of miR-195 on cell proliferation, migration, invasion and epithelial–mesenchymal transition (EMT), and evaluated whether these effects were correlated with DNA methylation of the miR-195 promoter.

Materials and methods

Clinical specimens

A total of 30 paired surgical resected PCa tissues and adjacent noncancerous tissues were obtained from the Third Affiliated Hospital of Sun Yat-sen University (Guangdong, China) between October 2017 and September 2018. All of the patients were confirmed not to receive any preoperative chemotherapy or radiotherapy. All collected specimens were snap frozen in liquid nitrogen promptly and kept at −80 °C for further experiments. Written informed consent was signed by all patients before enrollment in clinical trials. The current study was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (Guangdong, China), and the study conformed to the standards set by the Declaration of Helsinki.

Methylation-specific PCR

Genomic DNA was isolated from tissues or cell lines by DNA Tissue Kit (Qiagen, Duesseldorf, Germany) and applied to bisulfite modification by using the EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA, USA) according to the instruction’s observation protocol. For methylation-specific PCR (MSP), bisulfite-converted genomic DNA was used as a template, and specific primers design was carried out by using METHYL PRIMER EXPRESS v1.0 software (Applied Biosystems Inc., Foster City, CA, USA).

Cell culture and transfection

Four PCa cell lines, LNCAP, PC-3, DU145 and 22RV1, and a normal prostate epithelial cell line, RWPE-1, were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). LNCAP, PC-3 and 22RV1 cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA, USA). DU145 cells were cultured in the Dulbecco’s modified Eagle’s medium (Life Technologies, Carlsbad, CA, USA). RWPE-1 cells were grown in defined keratinocyte serum-free medium (Invitrogen, Carlsbad, CA, USA). All cells were grown in medium containing 10% FBS (Gibco) and incubated at 37 °C under a humidified atmosphere of 5% CO2.

For cell transfection, two cell lines (PC-3 or DU145) were cultured in six-well plates overnight until reaching 70–80% confluence. RiboBio (Guangzhou, China) has synthesized inhibitor of miR-195 inhibitor, mimics of miR-195 (miR-195 inhibitor: 5’‐GCCAAAUUUCUGUGCU-GCUA‐3’; miR-195 mimics: 5’‐UAGCAGCACAGAAUAUUGGC‐3’; 5’‐CAAUAUUCUGUGCUCAUU‐3’) and corresponding negative control (miR-NC, 5’‐CAGUACUUUUGUGUAGUACAA‐5’). At a final concentration of 50 nM, transfection was carried out using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s protocols.

BSP

For BSP, bisulfite-converted genomic DNA was amplified with primers specific for BSP (designed using METHYL PRIMER EXPRESS v1.0, Applied Biosystems Inc) and then cloned into pMD19-T (TaKaRa, Dalian, China). Subsequently, five independent clones from each sample were sequenced on iCycler Thermal Cycler (Eppendorf, Hamburg, Germany).

Quantitative real-time PCR

Total RNA was extracted from tissues or cell lines using TRIzol reagent (Invitrogen), and cDNA was generated using random primers. Using the LightCycler 480 II Real-Time PCR system (Roche Diagnostics, Basel, Switzerland), the level of miR-195 was evaluated with SYBR Green PCR Master Mix of Hairpin-miRNA RT-PCR Quantitation Kit (GenePharma, Shanghai, China). Relative quantification of miR-195 was analyzed using the 2−ΔΔCT method with U6 snRNA as endogenous control. The primer sequences used were as follows: miR-195

5′‐CAAAAGTCAAGGCTCCTCTCT‐3′ (forward) and 5′‐GGTAGCTCTTCCCTCCTTAC‐3′ (reverse).
forward: 5’-ACACTCCAGCTGGGTAGCAGCACAGAAATATT-3’; reverse: 5’-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGCCAATA-3’; U6 forward: 5’-CTCGCTTCGGCAGCACA-3’; reverse: 5’-AACGCTTCACGAATTTGCGT-3’; epithelial marker (E-cadherin) forward: 5’-CGAGAGCTACACGTTCACGG-3’; reverse: 5’-GGGTGTCGAGGGAAAAATAGG-3’; mesenchymal marker (N-cadherin) forward: 5’-TCAGGCGCTCTGAGAGGCTT-3’; reverse: 5’-ATGCACATCCTCCATATGAAGACTG-3’. glycer-aldehyde-3 phosphate dehydrogenase forward: 5’-GGAGCGAGATCCCTCCAAAAT-3’; reverse: 5’-A GGCTGTTGTCACTTCTCATGG-3’.

Fig. 1. miR-195 was down-regulated in PCa tissues and cell lines. Quantitative real-time PCR was performed to determine miR-195 expression in (A) 30 paired tumor tissues and matched adjacent tissues, as well as in (B) PCa cell lines (LNCAP, PC-3, DU145 and 22RV1) and one normal prostate epithelial cell line, RWPE-1. The data are presented as the mean ± SD; n = 3; *P < 0.05, ***P < 0.001, compared with adjacent tissues or RWPE-1 cells; two-tailed Student’s t-test.

Fig. 2. miR-195 suppresses PCa cell proliferation in vitro. (A) miR-195 expression was significantly up-regulated after transfection with miR-195 mimics in PC-3 and DU145 cells. (B, C) CCK-8 assay revealed that miR-195 suppresses PCa cell proliferation. (D) Annexin V/PI double staining with flow cytometry analysis of PC-3 and DU145 cells transfected with miR-195 mimics. The data are presented as the mean ± SD; n = 3; **P < 0.01, ***P < 0.001, compared with miR-NC; two-tailed Student’s t-test.
Cell proliferation assay
PC-3 or DU145 cells from different groups were grown in 96-well plates (2 x 10^3 cells/well) and cultured overnight. At multiple time points (24, 48, and 72 h, respectively), 10 μL of Cell Counting Kit-8 solution (CCK-8; Dojindo, Kumamoto, Japan) was added into each well, and the cells were cultured for another 2 h at 37 °C. The absorbance (A) at 450 nm (A450 nm) was determined using a microplate reader (Bio-Tek ELX800; Winooski, VT, USA).

Cell apoptosis analysis
Flow cytometry assay was performed for cell apoptosis detection. In brief, approximately 3 x 10^5 cells from different groups were harvested, washed two times in PBS and then orderly stained with FITC-Annexin V and propidium iodide (PI) according to the FITC-Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA). Stained cells were analyzed by fluorescence-activated cell sorter using FACScan (BD Biosciences) equipped with CELL QUEST 3.0 software (BD, Franklin Lakes, NJ, USA).
Transwell assay

Transwell assay was carried out in PC-3 or DU145 cells from different groups using a 24-well Transwell chamber with 8‐µm pore size (Costar; Corning, Inc., Corning, NY, USA) without coated Matrigel (BD Biosciences) for cell migration or with coated Matrigel for cell invasion. In brief, 3 × 10^5 cells were transferred to the top chamber, and the chemoattractant (the medium containing 10% FBS) was added to the lower chamber. Following 24‐h incubation, 4% paraformaldehyde was used for fixation of those cells that migrated into the lower chamber; then, the cells were stained by 0.1% crystal violet; and finally, the cell counting was performed on a microscope (Olympus Corporation, Tokyo, Japan).

Western blot analysis

Total cellular protein was extracted from cells using ice-cold radioimmune precipitation assay buffer (Beyotime, Shanghai, China), and the concentration of protein was evaluated by the BCA protein assay kit (Beyotime). Twenty micrograms of protein was separated by 10% SDS/PAGE and then transferred to polyvinylidene fluoride membranes (Merck Millipore, Darmstadt, Germany). After blocking with 5% nonfat milk, the membranes were incubated with primary antibodies against E-cadherin, N-cadherin and glyceraldehyde-3 phosphate dehydrogenase overnight at 4 °C, followed by incubation with a secondary, horseradish peroxidase-conjugated antibody (Cell Signaling Technology, Danvers, MA, USA) for 1 h at room temperature. Then, these protein bands were measured using an enhanced chemiluminescence detection kit (Pierce; Thermo Fisher Scientific, Inc, Basingstoke, United Kingdom). Glyceraldehyde-3 phosphate dehydrogenase was used as an internal control.

Statistical analysis

All experiments were carried out in at least triplicate. Analysis of statistical data was conducted with spss version 21.0 software (IBM Corp., Armonk, NY, USA). Data were expressed as mean ± SD. For comparison between two groups, Student’s t‐test was performed. For groups of more than three groups, one‐way ANOVA was performed. Statistical tests were considered significant when the P‐value was less than 0.05.
Results

miR-195 expression was down-regulated in PCa tissues and cell lines

To investigate the role of miR-195 in PCa, we analyzed the relative expression of miR-195 in 30 pairs of PCa and adjacent tissues using quantitative real-time PCR. As shown in Fig. 1A, miR-195 expression was dramatically down-regulated in PCa tissues compared with paired adjacent tissues (P < 0.001). In a further analysis, endogenous expression of miR-195 was determined in four PCa cell lines, LNCAP, PC-3, DU145 and 22RV1, and a normal prostate epithelial cell line, RWPE-1. All four PCa cell lines exhibited relatively low miR-195 expression in comparison with RWPE-1 cells (Fig. 1B).

miR-195 overexpression significantly suppressed malignant biological behaviors of PCa cells

We overexpressed miR-195 in PCa cell lines by transfecting miR-195 mimics into PC-3 and DU145 cells with relatively lower miR-195 expression. We demonstrated that miR-195 expression profiles were significantly increased in both PC-3 and DU145 cells after transfection with miR-195 mimics (Fig. 2A, P < 0.001). Subsequently, a significant reduction in PC-3 (Fig. 2B, P < 0.01) and DU145 (Fig. 2C, P < 0.01) cell proliferation was observed in the miR-195 mimics group at 48 and 72 h. Annexin V/PI double staining revealed that the proportion of apoptosis was increased in PC-3 and DU145 cells after transfection with miR-195 mimics (Fig. 2D, P < 0.001). In addition, the protein level of Bax was significantly increased, whereas Bcl2 in PC-3 and DU145 cells was decreased by miR-195 overexpression (Fig. S1). As shown in Fig. 3A, miR-195 mimics–transfected PC-3 and DU145 cells underwent an obvious reduction in migratory activity (P < 0.001) and invasion ability (Fig. 3B, P < 0.01). Western blot analysis (Fig. 3C) exhibited that up-regulation of miR-195 increased the expression of E-cadherin and inhibited the expression of N-cadherin. These findings suggest that down-
regulated miR-195 might be an important cause for uncontrolled PCa cell proliferation, migration and invasion.

**miR-195 expression was regulated by DNA methylation of its promoter**

To explore the upstream mechanism implicated in miR-195 down-regulation in PCa, we analyzed the DNA methylation status of miR-195 promoter using MSP. As shown in Fig. 4A, hypermethylation of the miR-195 promoter was frequently observed in tumor samples (8/10) in comparison with paired adjacent normal tissues (2/10). To validate the importance of promoter methylation in the regulation of miR-195 levels, we treated PC-3 and DU145 cells with DNA methylation inhibitor 5-AzaC. BSP analysis demonstrated that 5-AzaC treatment obviously decreased the methylated CG sites in both PC-3 (Fig. 4B) and DU145 (Fig. 4C) cells. We analyzed the correlation between the methylation status and miR-195 mRNA levels in the individual paired N and T samples, and found the methylation level was negatively related with the miR-195 mRNA levels (Fig. 4D). Meanwhile, miR-195 expression was detected by quantitative real-time PCR. As shown in Fig. S2, the expression of miR-195 was notably restored in these two PCa cell lines (P < 0.001).
Elevated PCa cell progression was closely correlated with DNA methylation of the miR-195 promoter

Subsequently, we wondered whether 5-AzaC regulated PCa cell progression through directly elevating miR-195 expression. PC-3 and DU145 cells were treated with 5-AzaC, followed by transfection with miR-195 inhibitor or miR-NC. As shown in Fig. 5A, the expression of miR-195 was significantly up-regulated after 5-AzaC treatment alone (P < 0.001), but notably decreased after miR-195 inhibitor transfection in both PC-3 and DU145 cells (P < 0.01). As expected, a series of functional assays, including CCK-8 (Fig. 5B,C), flow cytometry (Fig. 5D) and transwell assays (Fig. 6A,B), demonstrated that the inhibition of cell proliferation, migration and invasion, and the increased cell apoptosis after 5-AzaC treatment were remarkably reversed by miR-195 inhibitor transfection in PC-3 and DU145 cells. We also demonstrated that 5-AzaC treatment enhanced the expression of Bax and decreased the level of Bcl2. However, the effect on the expression of Bax and Bcl2 was reversed by miR-195 inhibitor transfection in PC-3 and DU145 cells. Moreover, the suppressive effects of 5-AzaC on EMT markers (E-cadherin and N-cadherin) were abolished by miR-195 down-regulation in PC-3 and DU145 cells (Fig. 6C). These data further suggest that down-regulated miR-195 promoted PCa cell progression associated with DNA methylation of its promoter.

Unlike mutation, DNA methylation can be reversed, similar to other physiological biochemical modifications [36]. 5-Aza-dC as an approved demethylating agent by the U.S. Food and Drug Administration underscores the usefulness of epigenetic therapy by inducing tumor cell growth and apoptosis [37,38]. Based on the study by Ghoshal et al. [39], intraperitoneal injection of 5-AzaC completely attenuated growth of a transplanted tumor through demethylating and activating the antioxidant gene encoding metallothioneins. It has been shown that miR-1 is expressed at low levels in the HCC cell line, whereas 5-AzaC-mediated overexpression of miR-1 could reverse many characteristics of cancer cells, including growth, colony formation and resistance to apoptosis [36]. Recently, 5-AzaC as a demethylating agent has been used for regulating specific genes in PCa [40–42]. Consistently, we further demonstrated that the suppressive impact of 5-AzaC on the proliferation, migration and invasion ability of PCa cells may be partially because of demethylation and reactivation of miR-195.

In summary, this study confirmed that decreased miR-195 expression in PCa tissues and cell lines was linked to promoter methylation status. These results further emphasize that miR-195 is modulated by epigenetic mechanisms and functions as a crucial tumor suppressor in PCa, which might offer another molecular mechanism for PCa pathogenesis.

Discussion

In this study, we observed that miR-195 expression was dramatically decreased in PCa tissue and cell lines. In addition, enforced expression of miR-195 potentially blocked cell proliferation, migration, invasion and EMT in PCa cell lines, PC-3 and DU145. These results suggest that miR-195 may serve as a tumor suppressor in PCa. Despite different PCa cell lines, our data were consistent with the studies from Cai et al. [27,30], Guo et al. [28] and Liu et al. [29].

Related studies showed methylation in CpG islands could epigenetically regulate the transcription of miRNAs [34,35]. Another related study showed that down-regulation of miR-195 in HCC is attributed, maybe not all but at least in part, to the hypermethylation of CpG sequences in its promoter [33]. Here, we further explored whether decreased miR-195 expression was ascribed to higher DNA methylation level of promoter region by MSP analysis. As expected, hypermethylation of the promoter region of miR-195 may be an important mechanism mediating its down-regulation in PCa.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

XW conceived and designed the experiments. XM, LZ, ZC, XL and LW performed the experiments. XM and LZ analyzed the data. XW and XM wrote the paper. All authors read and approved the final manuscript.

References

1 Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, Ng CF and Sung JJ (2016) Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol 70, 862–874.

2 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136, E359–E386.
3 Quinn DI, Shore ND, Egawa S, Gerritsen WR and Fizazi K (2015) Immunotherapy for castration-resistant prostate cancer: progress and new paradigms. Urol Oncol 33, 245–260.

4 Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22.

5 Foley R, Hollywood D and Lawler M (2004) Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. Endocr Relat Cancer 11, 477–488.

6 Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP et al. (2017) Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359–364.

7 Packer JR and Maitland NJ (2016) The molecular and cellular origin of human prostate cancer. Biochem Biophys Acta 1863, 1238–1260.

8 Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10, 687–692.

9 Fang Z, Olkhovermitsel E, Kwast TVD, Sykes J, Zdravic D, Venkateswaran V, Zlotta AR, Loblaw A, Fleshner NE and Klots L (2017) Urinary DNA methylation biomarkers for noninvasive prediction of aggressive disease in patients with prostate cancer on active surveillance. J Urol 197, 335–341.

10 Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH et al. (2011) Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 129, 2454–2462.

11 Olkhover-Mitsel E, Kwast TVD, Kron K, Ozcelik H, Briollais L, Massaey C, Recker F, Kwiatkowski M, Fleshner N and Diamandis E (2012) Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 7, 1037–1045.

12 Chakraborty C, Sharma AR, Sharma G, Sarkar BK and Lee SS (2018) The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. Oncotarget 9, 10164–10174.

13 Wang Y, Wang L, Chen C and Chu X (2018) New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. Mol Cancer 17, 22.

14 Luo B, Kang N, Chen Y, Liu L and Zhang Y (2017) Oncogene miR-106a promotes proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro. Minerva Med 109, 24.

15 Song XL, Huang B, Zhou BW, Wang C, Liao ZW, Yu Y and Zhao SC (2018) miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3beta. Biomed Pharmacother 99, 369–374.

16 Chang YL, Zhou PJ, Wei L, Li W, Ji Z, Fang YX and Gao WQ (2015) MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway. Oncotarget 6, 24017–24031.

17 Kojima S, Enokida H, Yoshino H, Itesako T, Chiyomaru T, Kinoshita T, Fuse M, Nishikawa R, Goto Y, Naya Y et al. (2014) The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet 59, 78–87.

18 Qian S, Xian Z, Xin L, Yanli W, Jian H, Bing J, Qin C and Jianxiu Y (2015) miR-146a functions as a tumor suppressor in prostate cancer by targeting Rac1. Prostate 74, 1613–1621.

19 Bhatia V, Yadav A, Tiwari R, Nigam S, Goel S, Carskadon S, Gupta N, Goel A, Palanisamy N and Ateeq B (2019) Epigenetic silencing of miRNA-338-5p and miRNA-421 Drives SPINK1-positive prostate cancer. Clin Cancer Res 25, 2755–2768.

20 Yu W, Liang X, Li X, Zhang Y, Sun Z, Liu Y and Wang J (2018) MicroRNA-195: a review of its role in cancers. OncoTargets Ther 11, 7109–7123.

21 Guo AY, Sun J, Jia P and Zhao Z (2010) A novel microRNA and transcription factor mediated regulatory network in schizophrenia. BMC Syst Biol 4, 10.

22 Eva VR, Sutherland LB, Ning L, Williams AH, John MA, Gerard RD, Richardson JA and Olson EN (2006) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103, 18255–18260.

23 Yang G, Liu Z, Wang L, Chen X, Wang X, Dong Q, Zhang D, Yang Z, Zhou Q, Sun J et al. (2018) MicroRNA-195 protection against focal cerebral ischemia by targeting CX3CR1. J Neurosurg 131, 1445–1454.

24 Nadeem F, Hanif M, Ahmed A, Jamal Q and Khan A (2017) Clinicopathological features associated to MiRNA-195 expression in patients with breast cancer: evidence of a potential biomarker. Pak J Med Sci 33, 1242–1247.

25 Yang X, Yan Z, Yang H, Ni H, Zhang L and Wang Y (2019) Clinical value of combined detection of miR-1202 and miR-195 in early diagnosis of cervical cancer. Oncol Lett 17, 3387–3391.

26 Chen X and Wang A (2019) Clinical significance of miR-195 in hepatocellular carcinoma and its biological function in tumor progression. OncoTargets Ther 12, 527–534.
Demethylation of miR-195 in prostate cancer

X. Ma et al.

27 Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR et al. (2015) miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. *Clin Cancer Res* **21**, 4922–34.

28 Guo J, Wang M and Liu X (2015) MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma. *J Exp Clin Cancer Res* **34**, 91.

29 Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang L, Lu K, Tao T, Zhang X and Huang Y (2015) miR-195 inhibits EMT by targeting FGF2 in prostate cancer cells. *PLoS ONE* **10**, e0144073.

30 Cai C, He H, Duan X, Wu W, Mai Z, Zhang T, Fan J, Deng T, Zhong W, Liu Y et al. (2018) miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression. *Oncol Rep* **39**, 1658–1670.

31 Ma X, Zou L, Li X, Chen Z, Lin Q and Wu X (2018) MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer. *Biomed Pharmacother* **99**, 445–450.

32 Zhang JY, Li YN, Mu X, Pan ZL and Liu WB (2018) Targeted regulation of miR-195 on MAP2K1 for suppressing ADM drug resistance in prostate cancer cells. *Eur Rev Med Pharmacol Sci* **22**, 8599–8608.

33 He XX, Kuang SZ, Liao JZ, Xu CR, Chang Y, Wu YL, Gong J, Tian DA, Guo AY and Lin JS (2015) The regulation of microRNA expression by DNA methylation in hepatocellular carcinoma. *Mol BioSyst* **11**, 532–539.

34 Poddar S, Kesharwani D and Datta M (2017) Interplay between the miRNome and the epigenetic machinery: implications in health and disease. *J Cell Physiol* **232**, 2938–2945.

35 Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, Kimura T, Kudo T, Harada E, Sugai T et al. (2010) Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. *Carcinogenesis* **31**, 2066–2073.

36 Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD et al. (2008) Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. *Cancer Res* **68**, 5049–5058.

37 Mai A and Altucci L (2009) Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. *Int J Biochem Cell Biol* **41**, 199–213.

38 Muraki Y, Banno K, Yanokura M, Kobayashi Y, Kagawuchi M, Nomura H, Hirasawa A, Susumu N and Aoki D (2009) Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (review). *Oncol Rep* **22**, 967–972.

39 Ghoshal K, Majumder S, Li Z, Dong X and Jacob ST (2000) Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation. *J Biol Chem* **275**, 539–547.

40 Yu JD, Yang K, Mao QQ, Kong DB, Zheng XY and Xie LP (2009) Estrogen in combination with 5-azacitidine up-regulates p75NTR expression and induces apoptosis in 22Rv1 prostate cancer cells. *Mol Med Rep* **2**, 831–836.

41 Dasari VK, Deng D, Perinchery G, Yeh CC and Daihya R (2002) DNA methylation regulates the expression of Y chromosome specific genes in prostate cancer. *J Urol* **167**, 335–338.

42 Walton TJ, Li G, Seth R, McArdle SE, Bishop MC and Rees RC (2008) DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. *Prostate* **68**, 210–222.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** (A) The expression of Bax and Bcl2 proteins in PC-3 and DU145 cells transfected with miR-195 mimics or control was analyzed by western blot. (B) PC-3 and DU145 cells were treated with 5-AzaC, followed by transfection with miR-195 inhibitor or miRNA. The expression of Bax and Bcl2 proteins in PC-3 and DU145 cells transfected with miR-195 mimics or control was analyzed by western blot. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

**Fig. S2.** The expression of miR-195 was determined in PC-3 and DU145 cells treated with 5-AzaC using quantitative real-time PCR analysis. The data are presented as the mean ± SD; *n = 3*; ***P < 0.001, compared with control; two-tailed Student’s *t*-test.